Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant letrozole ± zoledronic acid in postmenopausal women with hormone receptor–positive breast cancer
2004-004007-37Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Letrozole monotherapy with Letrozole + zoledronic acid (2 arms). Primary endpoint: Tumor response at 6 months (modified RECIST). Started Mar 2006; status: completed.
02
Drugs
letrozolezoledronic acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-004007-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004007-37.